Voyager Therapeutics, Inc. (VYGR) stock
VYGRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/3040% below fair value
$1.73+0.03 (+1.76%)
Close on Nov 13, 2026Market cap $106.60MP/E –Yield –
Voyager Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Voyager Therapeutics's profit margin for the twelve months ending Sep 30, 2026 was -416.3%. For fiscal 2025 it was -296.5%, against -81.3% the year before. The highest annual figure on record is 52.9% in fiscal 2023.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -296.5% | −215.3 |
| FY2024 | Dec 31, 2024 | -81.3% | −134.2 |
| FY2023 | Dec 31, 2023 | 52.9% | +166.4 |
| FY2022 | Dec 31, 2022 | -113.4% | +76.8 |
| FY2021 | Dec 31, 2021 | -190.3% | −211.8 |
| FY2020 | Dec 31, 2020 | 21.5% | +63.2 |
| FY2019 | Dec 31, 2019 | -41.8% | +1117.0 |
| FY2018 | Dec 31, 2018 | -1158.8% | −461.2 |
| FY2017 | Dec 31, 2017 | -697.6% | −414.9 |
| FY2016 | Dec 31, 2016 | -282.7% | −111.5 |
| FY2015 | Dec 31, 2015 | -171.2% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -615.2% | −406.5 |
| Q2 FY2026 | Jun 30, 2026 | -773.2% | −131.3 |
| Q1 FY2026 | Mar 31, 2026 | -1077.4% | −598.2 |
| Q4 FY2025 | Dec 31, 2025 | -178.8% | +370.5 |
| Q3 FY2025 | Sep 30, 2025 | -208.7% | −172.0 |
| Q2 FY2025 | Jun 30, 2025 | -642.0% | −607.7 |
| Q1 FY2025 | Mar 31, 2025 | -479.2% | −421.2 |
| Q4 FY2024 | Dec 31, 2024 | -549.3% | −611.9 |
| Q3 FY2024 | Sep 30, 2024 | -36.7% | +524.6 |
| Q2 FY2024 | Jun 30, 2024 | -34.3% | +423.3 |
| Q1 FY2024 | Mar 31, 2024 | -58.1% | −140.5 |
| Q4 FY2023 | Dec 31, 2023 | 62.6% | +19.7 |
| Q3 FY2023 | Sep 30, 2023 | -561.4% | +2119.4 |
| Q2 FY2023 | Jun 30, 2023 | -457.6% | +2782.4 |
| Q1 FY2023 | Mar 31, 2023 | 82.4% | +62.1 |
| Q3 FY2022 | Sep 30, 2022 | 42.9% | +1739.0 |
| Q2 FY2022 | Jun 30, 2022 | -2680.8% | −461.2 |
| Q1 FY2022 | Mar 31, 2022 | -3240.0% | −2907.0 |
| Q4 FY2021 | Dec 31, 2021 | 20.3% | +264.0 |
| Q3 FY2021 | Sep 30, 2021 | -1696.2% | −1768.8 |
| Q2 FY2021 | Jun 30, 2021 | -2219.6% | −2189.3 |
| Q1 FY2021 | Mar 31, 2021 | -333.0% | −198.7 |
| Q4 FY2020 | Dec 31, 2020 | -243.6% | −205.1 |
| Q3 FY2020 | Sep 30, 2020 | 72.6% | +146.1 |
| Q2 FY2020 | Jun 30, 2020 | -30.3% | −54.5 |
| Q1 FY2020 | Mar 31, 2020 | -134.3% | +388.5 |
| Q4 FY2019 | Dec 31, 2019 | -38.5% | +1083.6 |
| Q3 FY2019 | Sep 30, 2019 | -73.4% | +895.5 |
| Q2 FY2019 | Jun 30, 2019 | 24.2% | +1016.1 |
| Q1 FY2019 | Mar 31, 2019 | -522.8% | +1592.5 |
| Q4 FY2018 | Dec 31, 2018 | -1122.1% | −935.7 |
| Q3 FY2018 | Sep 30, 2018 | -968.9% | +1064.7 |
| Q2 FY2018 | Jun 30, 2018 | -991.9% | +611.9 |
| Q1 FY2018 | Mar 31, 2018 | -2115.3% | −978.1 |
| Q4 FY2017 | Dec 31, 2017 | -186.4% | +434.8 |
| Q3 FY2017 | Sep 30, 2017 | -2033.6% | – |
| Q2 FY2017 | Jun 30, 2017 | -1603.7% | – |
| Q1 FY2017 | Mar 31, 2017 | -1137.2% | – |
| Q4 FY2016 | Dec 31, 2016 | -621.2% | – |
See a number that looks wrong?